Health Executive Insights
Former Johnson & Johnson ANZ Managing Director, Gavin Fox-Smith on working in large & small MedTech companies
▶︎ Career turning points
▶︎ Making an impact at J&J|
▶︎ Working in small business
▶︎ Working at Omnigon
▶︎ Taking opportunities
▶︎ Impact of MedTech in society
You Might also like
-
New treatment options under investigation for pelvic organ prolapse
Dr Shayanti Mukherjee, Research Group Head, Translational Tissue Engineering at the with her team at Hudson Institute of Medical Research is developing new ways to prevent and potential cure pelvic organ prolapse (POP). The technology aims to ultimately lead to safer and more effective treatment for women with pelvic organ prolapse (POP) using a woman’s own stem cells to boost the effectiveness of a degradable mesh.
-
SAHMRI Celebrates 10 Years of Research
SAHMRI represents an exciting and unique statewide concept, bringing together basic and translational research, South Australia’s three universities and the health system. SAHMRI works in collaboration with its partners to provide a clear focal point for health and medical research, including paving the way for new partnerships, innovative research projects and improved health outcomes.
Executive Director, Professor Maria Makrides spoke to Australian Health Journal about 3 achievements in the past 10 years that have had significant impact
International leadership breakthroughs in leukaemia research
Culturally appropriate Indigenous health research and clinical care
Omega 3 fatty acids as a preterm birth prevention -
Foundation outlines breast cancer research strategy
Australian Health Journal met with Associate Professor Cleola Anderiesz, CEO of the National Breast Cancer Foundation to hear of the new 5 year Pink Horizon research strategy. Those with lived experience of breast cancer, along with researchers, clinicians, and other funding organisations, have contributed to the development of the foundation’s new five-year Pink Horizon research strategy. This ambitious plan aims to invest $125 million to accelerate research efforts towards the vision of ending deaths from breast cancer.